Fujisawa plans expansion of reagent sales:
This article was originally published in Clinica
Fujisawa (Japan) has reported diagnostic reagent sales for 1994 of approximately ¥,700 million ($17 million), according to Japan Medical Review (October). Although reagents currently account for less than 1% of Fujisawa's overall turnover, the company is aiming at "aggressive" development of this market. Under a recent distribution deal concluded with US company Vysis (see Clinica No 667, p 9), Fujisawa will start marketing a Vysis genetic analysis kit in Japan later this year.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.